Navigation Links
Prasco® Launches Authorized Generic with Shionogi Inc.
Date:8/22/2011

CINCINNATI, Aug. 22, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Nitrofurantoin Oral Suspension, the Authorized Generic version of Furadantin® Oral Suspension. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.

"Prasco is pleased to work with Shionogi to extend another of its brands, Furadantin® Oral Suspension, into our Authorized Generic product line as Nitrofurantoin Oral Suspension," said Prasco Chief Executive Officer E. Thomas Arington. "This agreement expands our relationship with Shionogi, a leading global pharmaceutical company."

Today's announcement between Shionogi and Prasco comes after another similar agreement between the two companies earlier this year.

The leader in Authorized Generics, Prasco has now brought 33 Authorized Generics to market, more than any other company. Prasco Authorized Generics are identical to brand products. Established brand companies work with Prasco to bring their brands to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists.

Nitrofurantoin Oral Suspension is AB-rated, therapeutically equivalent and substitutable for the brand Furadantin® Oral Suspension.  For additional important information, please click here for full prescribing information, or visit www.prasco.com

Furadantin® is a registered trademark of Shionogi Inc.

About Prasco Laboratories

Prasco is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics.  Prasco Authorized Generics provide patients with the identical experience of a branded drug at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit prasco.com.  

FUR11-PPR-001-00


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
2. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
3. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
4. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
5. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Market? Which areas are going to grow at the ... to 2026, assessing data, trends, opportunities and prospects. ... Discover the most lucrative areas in the industry and ... assess forecasted sales across the all the major categories ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing their participation ... Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in ... program. , “We know it’s easy to get carried away when you’re ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline ... been condensed to a single page, maximizing usability and improving efficiency significantly for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):